We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Flow State (The Tenth Co Pty Ltd)
Product Name
Flow State
Sponsor
ARTG details
- 399003
Date of review outcome
Date of publication
Jun-2025
Outcome
Medicine continues to be permitted for supply. Batches released after September 2024 must carry corrected labels.
Is it safe to continue using this medicine?
Yes, however, use of the medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
If you are concerned about the health of yourself or your baby, talk to your health practitioner.
Seek advice from a doctor if you have been using this medicine to treat depression or anxiety.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to the above conditions as well as for promoting maternal postnatal health, promoting skin health and improving mood.
Be aware this medicine is not a substitute for good nutrition or superior to a balanced diet.
Seek advice from a doctor if you have been using this medicine to treat depression or anxiety.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to the above conditions as well as for promoting maternal postnatal health, promoting skin health and improving mood.
Be aware this medicine is not a substitute for good nutrition or superior to a balanced diet.
Review scope
Targeted
Information reviewed
ARTG Record, Labels, Manufacturing Documentation, Website
Issues related to safety
The label and website for this medicine contained claims related to helping promote maternal postnatal health. This claim requires the warning statement set out under ‘What action should consumers take?’ above. However, the label and website did not include this warning statement, which is necessary to ensure the safe use of the medicine and to alert consumers to safety risks prior to taking the medicine.
The label and website also contained claims specified in 'What action should consumers take?' above. Some of these claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to delay consumer access to timely advice or treatment from a suitably qualified health professional, which may result in adverse outcomes.
The website contained claims that this medicine was a substitute for good nutrition and superior to a balanced diet. Vitamin or mineral supplements are prohibited from making this claim unless permission has been given by the TGA.
While advertising of this nature is unacceptable, the labels of the affected batches have been corrected, and the claims have been removed from the label and website. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
The label and website also contained claims specified in 'What action should consumers take?' above. Some of these claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to delay consumer access to timely advice or treatment from a suitably qualified health professional, which may result in adverse outcomes.
The website contained claims that this medicine was a substitute for good nutrition and superior to a balanced diet. Vitamin or mineral supplements are prohibited from making this claim unless permission has been given by the TGA.
While advertising of this nature is unacceptable, the labels of the affected batches have been corrected, and the claims have been removed from the label and website. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The ARTG record, label and website for this medicine contained claims specified in ‘What action should consumers take?’ above. However, these claims were not covered by the sponsor’s certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor corrected the affected batches and updated their label and website to correct the issues.
Nevertheless, the TGA issued an educational letter to the sponsor outlining the issues with this medicine.
Nevertheless, the TGA issued an educational letter to the sponsor outlining the issues with this medicine.